A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies
The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656.
The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Institut de Recherches Internationales Servier (I.R.I.S.)
- Telefoonnummer: +33 1 55 72 60 00
- E-mail: scientificinformation@servier.com
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- Investigator-assessed life expectancy of ≥ 3 months.
- Able and willing to comply with requirements of the study protocol.
- Documented genetic characterization of the disease as per local practice.
- Clinical and laboratory thresholds:
- Cytoreduction: white blood cell (WBC) < 25 × 10⁹/L (hydroxyurea/cytarabine/leukapheresis allowed).
- Renal: creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault).
- Hepatic: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN) (5 × if leukemic); Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome).
- Part 1 Only: Relapsed/Refractory (R/R), pathologically confirmed AML, MDS/AML, or CMML.
- Part 1 Only: Must have failed ≥ 1 approved standard therapy and have no other approved standard options.
Exclusion Criteria:
- Known hypersensitivity to S241656, or Posaconazole (Part 1B).
- Pregnant or breastfeeding; positive serum pregnancy test for WOCBP.
- Diagnosis of acute promyelocytic leukemia (French-American-British [FAB] M3 classification), MPN, mixed/ambiguous lineage, histiocytic/dendritic cell neoplasms, or AML with isolated extramedullary disease (no marrow/blood involvement).
- Active Central Nervous System (CNS) disease (by cytologic or radiographic evidence).
- Failure to recover to ≤ Grade 1 from previous toxicities (except Grade 2 neuropathy/alopecia).
- Major surgery within 4 weeks.
- Any anticancer therapy within 2 weeks or 5 half-lives (28 days for biologics). Cytoreduction with hydroxyurea or cytarabine is permitted.
- Prior use of experimental KRAS/BRAF/MEK/ERK inhibitors (prior FLT3 inhibitors are permitted).
- Uncontrolled infections (human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) permitted only if viral load is undetectable/controlled and specific cluster of differentiation 4 (CD4)+ criteria are met).
- Malabsorption, Crohn's, or chronic vomiting that impacts oral drug absorption.
- History/risk of retinal vein occlusion (RVO), glaucoma, or hyper-viscosity syndromes.
- Other active malignancy requiring systemic therapy within 2 years (except non-melanoma skin cancer or localized/cured tumors).
- Stroke, myocardial infarction (MI), unstable angina, or acute coronary syndrome within 6 months.
- Congestive heart failure (CHF), clinically significant cardiac arrhythmias according to the investigator's judgement (e.g., ventricular tachycardia), complete left bundle branch block and high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II- and third degree AV block).
- Fridericia-corrected QT interval (QTcF) > 470 msec or history of Torsades de pointes.
- Disseminated intravascular coagulation (DIC), significant coagulopathy according to the investigator's judgement, or uncontrolled bleeding.
- Proton Pump Inhibitors (PPIs) and potassium-competitive acid blockers ≥ 7 days prior to Cycle 1 Day 1.
- Breast cancer resistance protein (BCRP) sensitive substrate or with a narrow therapeutic index (NTI)
- All herbal preparations/supplements are prohibited.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Part 1A: Dose Escalation
|
Tablets taken by mouth.
|
|
Experimenteel: Part 1B: Optional Drug-Drug Interaction [DDI] Substudy
|
Tablets taken by mouth.
Tablets taken by mouth
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
(Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment
Tijdsspanne: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1A and 1B) Number of Adverse Events (AEs)
Tijdsspanne: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of Serious Adverse Events (SAEs)
Tijdsspanne: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of AEs
Tijdsspanne: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of SAEs
Tijdsspanne: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of AEs
Tijdsspanne: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of SAEs
Tijdsspanne: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in safety laboratory results
Tijdsspanne: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in physical examination
Tijdsspanne: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose reductions due to AEs
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose interruptions due to AEs
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose delays due to AEs
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of study withdrawals due to AEs
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1B only) Maximum concentration (Cmax) of S241656
Tijdsspanne: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Cmax of metabolite S243796
Tijdsspanne: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Time corresponding to Cmax (Tmax) of S241656
Tijdsspanne: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Tmax of metabolite S243796
Tijdsspanne: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Terminal half-life (t1/2) of S241656
Tijdsspanne: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) t1/2 of metabolite S243796
Tijdsspanne: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Area under the curve (AUC) of S241656
Tijdsspanne: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) AUC of metabolite S243796
Tijdsspanne: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
(Part 1A only) Cmax of S241656
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Cmax of metabolite S243796
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of S241656
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of metabolite S243796
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of S241656
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of metabolite S243796
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of S241656
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of metabolite S243796
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission (CR)
Tijdsspanne: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission with incomplete hematologic recovery (CRi)
Tijdsspanne: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Morphologic leukemia free state (MLFS)
Tijdsspanne: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Complete remission with partial hematologic recovery (CRh)
Tijdsspanne: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Partial response (PR)
Tijdsspanne: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Objective response (OR)
Tijdsspanne: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Composite complete remission (CRc)
Tijdsspanne: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Red blood cell (RBC) and platelet transfusion independence for at least 8 weeks
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
In participants with AML or MDS/AML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of response (DOR)
Tijdsspanne: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Time to response (TTR)
Tijdsspanne: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Event free survival (EFS)
Tijdsspanne: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Overall survival (OS)
Tijdsspanne: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Marrow response
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of participants with erythroid-, neutrophil-, platelet or spleen-response
Tijdsspanne: Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata
- Chronische ziekte
- Ziekte attributen
- Genetische ziekten, aangeboren
- Neoplasmata per histologisch type
- Hematologische ziekten
- Leukemie, myeloïde
- Myelodysplastische-myeloproliferatieve ziekten
- Beenmergziekten
- Leukemie
- Myelodysplastische syndromen
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Pathologische aandoeningen, tekenen en symptomen
- Hemische en lymfatische ziekten
- GATA2-tekort
- Leukemie, myeloïde, acuut
- Leukemie, myelomonocytische, chronische
- posaconazol
Andere studie-ID-nummers
Andere studie-ID-nummers
- S241656-292
- 2025-525128-88-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- sponsored by Servier
- with a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .